Scientific Validation
CNSide™ CSF Assay Research
Explore the groundbreaking CNSide™ research that demonstrates increased sensitivity versus cytology and clinically relevant cerebrospinal fluid analyses in managing Leptomeningeal Metastases (LM).
Publications
The CNSide™ CSF assay significantly enhances clinical management for patients with Leptomeningeal Metastases (LM) by providing detailed molecular insights. This allows for more personalized treatment plans, timely interventions, and better monitoring of disease progression.
Wooster M. et al. Clinical Breast Cancer, 2022
Study Snapshot
Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ Assay
Sweed N. et al. Arch Path & Lab Med, 2024
Study Snapshot
A Microfluidic, Multi-Antibody Cell Capture Method to Evaluate Tumor Cells in Cerebrospinal Fluid in Patients with Suspected Leptomeningeal Metastases
Barbour A. et al. J of Neuro-Oncology, 2024
Study Snapshot
Prognostic Value of Cerebrospinal Fluid Tumor Cell Count in Leptomeningeal Disease from Solid Tumors
Rogawski D. et al. J of Neuro-Oncology, 2024
Durable Responses to Trastuzumab Deruxtecan in Patients with Leptomeningeal Metastases from Breast Cancer with Variable HER2 Expression
Appel H. et al. Neuro-Oncology Advances, 2024
Study Snapshot
Comparative Evaluation of the Diagnostic and Prognostic Performance of CNSide Versus Standard Cytology for Leptomeningeal Disease
Kumthekar P. et al. Frontiers in Oncology, 2024
Study Snapshot
The HER2 flip-HER2 Amplification of Tumor Cells in the CSF of Breast Cancer Patients with Leptomeningeal Disease: Implications for Treating the LM Tumor with Anti-HER2 Therapy
Puri S. et al. Neuro-Oncology Advances, 2023
Study Snapshot